+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Opioid Induced Constipation Market by Product Type (Combination Therapies, Laxatives, Peripherally Acting Mu-Opioid Receptor Antagonists), Oral (Liquid, Solid), Rectal - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715749
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Opioid Induced Constipation Market grew from USD 70.10 million in 2024 to USD 75.03 million in 2025. It is expected to continue growing at a CAGR of 6.77%, reaching USD 103.86 million by 2030.

Setting the Stage for a Deep Dive into Opioid Induced Constipation Highlighting Clinical Challenges and Unmet Patient Needs Under Evolving Treatment Paradigms

Opioid induced constipation (OIC) represents one of the most prevalent and burdensome adverse effects experienced by patients undergoing opioid therapy for both acute and chronic pain conditions. Characterized by infrequent bowel movements, straining, and hard or lumpy stools, OIC arises when opioid medications bind to mu-opioid receptors within the gastrointestinal tract, slowing peristalsis and disrupting normal digestive function. Beyond the physical discomfort, patients often face emotional distress and reduced adherence to analgesic regimens, potentially compromising pain management and overall quality of life.

With opioid prescriptions continuing to serve as a cornerstone in pain management protocols, the incidence of OIC remains closely tied to the global opioid utilization trend. Although laxatives and traditional bowel regimens have formed the first line of therapy, their limitations in efficacy and tolerability underscore the unmet clinical need driving innovation. Recent years have witnessed the emergence of specialized agents targeting peripheral mu-opioid receptors, offering new therapeutic avenues aimed at mitigating constipation without undermining analgesia.

This introduction provides critical context for understanding why stakeholders across the healthcare continuum must prioritize OIC management. Through a combination of patient-centric research, evolving treatment modalities, and strategic collaborations, the industry is poised to address this pressing challenge. As we embark on a detailed exploration of regulatory advances, market dynamics, and actionable strategies, the significance of OIC and its implications for clinicians, payers, and manufacturers will become increasingly clear.

Uncovering the Most Significant Transformations in Opioid Induced Constipation Treatment Due to Regulatory Advances and Innovative Therapeutic Approaches

Over the past decade, the opioid induced constipation landscape has undergone transformative shifts driven by regulatory approvals, scientific breakthroughs, and an amplified focus on patient-centered outcomes. Initially, management strategies relied heavily on general-purpose laxatives and stool softeners, which offered inconsistent relief and often required escalated dosing schedules. As clinicians and patients alike demanded more effective solutions, regulatory bodies responded by evaluating novel therapeutic classes that directly antagonize peripheral opioid receptors, thereby preserving analgesic efficacy while restoring gastrointestinal motility.

Concurrently, advances in drug formulation and delivery technologies have improved the bioavailability and tolerance profiles of emerging treatments. Innovations such as targeted oral antagonists and injectable agents have expanded the armamentarium available to prescribers, enabling more personalized approaches tailored to individual patient needs. In parallel, digital health platforms and remote monitoring tools have gained traction, facilitating closer patient engagement and real-time symptom tracking, which in turn guide therapy optimization.

These converging forces have fundamentally altered the competitive environment, creating new entry points for both established pharmaceutical companies and agile biotech innovators. As payers scrutinize value propositions and reimbursement criteria evolve, stakeholders must remain attuned to these shifts to capitalize on opportunities and anticipate future disruptions.

Cumulative Impact of 2025 United States Tariffs on Opioid Induced Constipation Treatment Landscape and Its Ripple Effects on Accessibility and Pricing Dynamics

The implementation of United States tariffs in 2025 has introduced a range of cost pressures impacting both manufacturers of opioid induced constipation therapies and the broader supply chain of active pharmaceutical ingredients. As tariffs on key raw materials and intermediate compounds took effect, several manufacturers experienced increased production expenses, which in turn exerted upward pressure on overall treatment costs. These shifts have prompted companies to reevaluate sourcing strategies and accelerate initiatives to diversify supply networks.

Moreover, the tariff-induced cost escalation has influenced pricing negotiations with payers, driving stakeholders to explore alternative value-generation models. Outcomes-based contracting and risk-sharing agreements have gained prominence as mechanisms to balance affordability with patient access. At the same time, some manufacturers have responded by investing in domestic production facilities and backward integration to mitigate exposure to future tariff fluctuations, thereby safeguarding margins and ensuring a more stable supply of critical therapeutic agents.

Despite these challenges, the market has demonstrated resilience through adaptive pricing structures and strategic partnerships aimed at maintaining patient affordability. Importantly, the cumulative impact of the 2025 tariffs has served as a catalyst for innovation in procurement, manufacturing and distribution, reinforcing the necessity of flexible business models in an increasingly dynamic trade environment.

Gaining Critical Insights into Market Segmentation by Product Type Oral and Rectal Administration Routes to Uncover Key Opportunities and Therapeutic Differentiators

A nuanced understanding of market segmentation in opioid induced constipation reveals distinct opportunities and therapeutic differentiators across product type, oral and rectal administration routes. When examined by product type, the landscape encompasses combination therapies alongside a spectrum of laxatives that include osmotic agents designed to draw fluid into the bowel, stimulant options that increase peristaltic activity, and stool softeners that facilitate easier passage. Complementing these traditional agents, a class of peripherally acting mu-opioid receptor antagonists has emerged, comprising molecules such as alvimopan, methylnaltrexone, naldemedine and naloxegol, each engineered to selectively counteract opioid-induced gastrointestinal effects without influencing central analgesia.

Exploring oral delivery formats highlights the contrast between liquid formulations, which offer solutions and suspensions that can be precisely titrated and tailored to patient preferences, and solid dosage forms represented by capsules and tablets that prioritize stability and ease of administration. This dichotomy underscores the importance of convenience, bioavailability, and patient adherence in selecting the optimal therapy.

Simultaneously, rectal preparations play a critical role for patients requiring rapid onset or alternative administration pathways, with options ranging from enemas to suppositories. These products differentiate themselves through localized action and swift relief, making them essential tools within the therapeutic toolkit. By dissecting these segmentation layers, stakeholders can identify high-potential niches and align development efforts with evolving patient and clinician demands.

Illuminating Regional Patterns and Strategic Hotspots in the Opioid Induced Constipation Landscape Spanning Americas Europe Middle East Africa and Asia Pacific

Regional dynamics in opioid induced constipation management exhibit marked variations that inform strategic priorities for market entry, resource allocation and partnership development. In the Americas, the established infrastructure for pain management and high opioid utilization have translated into significant demand for advanced OIC therapies. Payers in this region increasingly emphasize outcomes-based models and real-world evidence to support formulary decisions, prompting manufacturers to demonstrate both clinical efficacy and economic value to secure coverage.

Across Europe, Middle East and Africa, heterogeneity in healthcare funding models and regulatory landscapes creates a complex environment for therapy rollout. While certain countries prioritize centralized procurement and national formulary inclusion, others rely on fragmented reimbursement frameworks. Overcoming these barriers requires nuanced market access strategies, including engagement with local health technology assessment bodies and adaptive pricing schemes tailored to regional budgetary constraints.

In contrast, the Asia-Pacific region is characterized by rapid growth in healthcare infrastructure and rising patient awareness. Expanding hospital networks and increasing investment in specialist pain management centers have opened avenues for new treatment adoption. However, variability in regulatory timelines and pricing controls necessitates proactive stakeholder engagement and robust evidence generation to facilitate accelerated entry into these markets. Understanding these regional contours allows companies to calibrate launch sequences and build sustainable commercial operations.

Exploring Strategic Positions of Leading Pharmaceutical and Biotech Companies Shaping the Competitive Environment for Opioid Induced Constipation Solutions

The competitive landscape for opioid induced constipation therapies is shaped by a balance between established pharmaceutical giants and emerging biotech innovators. Leading the charge are companies that have successfully navigated regulatory pathways to secure approval for targeted antagonists, carving out high-value niches in the broader laxative market. For instance, several global healthcare organizations have leveraged their development expertise to introduce peripherally acting mu-opioid receptor antagonists and fortified their portfolios through strategic acquisitions of niche biotech firms.

Simultaneously, mid-sized and regional players continue to refine their product offerings by focusing on formulation enhancements, patient adherence programs and value-driven contracting. Partnerships between multinational corporations and specialty distributors have become common, providing localized market insights while ensuring efficient distribution. Additionally, contract manufacturing organizations have expanded capacity to support both high-volume laxatives and lower-volume, high-value therapeutic antagonists.

Emerging companies specializing in digital health and patient support services are also gaining traction, integrating remote symptom monitoring, mobile applications and adherence reminders into comprehensive care pathways. These collaborations underscore a trend toward holistic solutions that extend beyond pharmacotherapy, positioning integrated platforms as a differentiator in an increasingly competitive space.

Identifying Actionable Strategies for Industry Leaders to Drive Growth Improve Patient Outcomes and Build Competitive Advantage in Opioid Induced Constipation

To capitalize on the evolving landscape of opioid induced constipation management, industry leaders should pursue a multi-faceted strategy that aligns innovation with patient needs and regulatory requirements. First, deepening investment in research and development for next-generation antagonists and combination products can drive differentiation, particularly when coupled with formulation technologies that enhance tolerability and adherence. Concurrently, establishing robust clinical evidence through real-world data initiatives will reinforce value propositions and support favorable reimbursement outcomes.

Second, forging strategic alliances with digital health providers and patient advocacy groups can elevate support services and enable personalized care, ultimately improving patient satisfaction and retention. These partnerships can facilitate remote symptom monitoring and provide actionable insights for clinicians, thereby optimizing therapy adjustments and reducing discontinuation rates.

Third, optimizing supply chain resilience through diversified sourcing, regional manufacturing and tariff mitigation strategies will safeguard against cost volatility. Companies should also explore flexible pricing and contracting approaches that align payment structures with patient outcomes, fostering stronger payer relationships.

By integrating these focus areas into a cohesive roadmap, organizations can strengthen their competitive positioning and deliver meaningful improvements in patient care.

Detailing Robust Research Design and Methodological Framework Ensuring Comprehensive Analysis High Data Integrity and Industry Relevancy for This Study

This research employs a rigorous mixed-methods approach to ensure comprehensive coverage and data integrity. Secondary sources, including peer-reviewed journals, regulatory filings and clinical trial registries, formed the foundation for historical context and therapy evolution. These insights were complemented by primary research encompassing in-depth interviews with key opinion leaders, clinical practitioners and patient advocacy representatives across multiple regions. Their perspectives provided nuanced understanding of treatment protocols, adoption barriers and emerging best practices.

Quantitative analysis included the triangulation of sales data, distribution metrics and payer coverage trends to map current market dynamics. Advanced statistical techniques were applied to validate correlations between therapeutic uptake and clinical outcomes. Additionally, case studies of strategic partnerships and real-world evidence programs were examined to identify success factors and replicable models.

The methodological framework also incorporated iterative validation steps, engaging external experts to review findings and ensure accuracy. Ethical considerations, data privacy compliance and transparency guidelines were strictly adhered to throughout the project lifecycle. This robust approach underpins the credibility of the insights presented in this report, equipping stakeholders with a reliable basis for strategic decision-making.

Synthesizing Key Findings and Strategic Implications to Provide a Cohesive Perspective on the Future Trajectory of Opioid Induced Constipation Management

In conclusion, the opioid induced constipation landscape stands at the nexus of clinical innovation, regulatory evolution and shifting market dynamics. The advent of specialized antagonists marks a paradigm shift from symptom management toward targeted intervention, while the 2025 tariff adjustments have underscored the importance of supply chain resilience and value-based pricing strategies. Segmentation analyses reveal distinct therapeutic niches across product type and administration routes, and regional insights highlight the need for tailored market access and commercialization plans.

Key players have capitalized on collaborative models that integrate pharmacological advances with digital health and patient support services, forging a more holistic approach to care. Moving forward, organizations that embrace real-world evidence generation, flexible contracting and strategic alliances will be best positioned to address unmet needs and navigate a complex reimbursement environment. Ultimately, the industry’s ability to deliver effective, accessible and patient-centric solutions will determine how successfully it meets the growing demands of clinicians and patients alike.

This executive summary provides a cohesive perspective, but ongoing vigilance in monitoring regulatory updates, payer policies and technological breakthroughs remains essential. By synthesizing these insights, stakeholders can chart a clear path toward sustainable growth and enhanced patient outcomes in the opioid induced constipation market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Combination Therapies
    • Laxatives
      • Osmotic Laxatives
      • Stimulant Laxatives
      • Stool Softeners
    • Peripherally Acting Mu-Opioid Receptor Antagonists
      • Alvimopan
      • Methylnaltrexone
      • Naldemedine
      • Naloxegol
  • Oral
    • Liquid
      • Solutions
      • Suspensions
    • Solid
      • Capsules
      • Tablets
  • Rectal
    • Enemas
    • Suppositories
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AstraZeneca plc
  • Shionogi & Co., Ltd.
  • H. Lundbeck A/S
  • Bausch Health Companies Inc.
  • Mundipharma International Limited
  • Merck & Co., Inc.
  • Valinor Pharma, LLC

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising uptake of peripherally acting mu-opioid receptor antagonists in hospitalized patients with chronic cancer pain management
5.2. Expansion of novel oral small molecule treatments targeting opioid-induced constipation symptoms in outpatient settings
5.3. Integration of digital therapeutics and mobile health apps for real-time monitoring of opioid-induced constipation severity
5.4. Increasing investment in extended-release combination opioid formulations with built-in constipation mitigation mechanisms
5.5. Impact of recent FDA label expansions for naloxegol and naldemedine on opioid-induced constipation treatment algorithms
5.6. Market penetration of linaclotide and plecanatide beyond irritable bowel syndrome for opioid-induced constipation off-label use
5.7. Adoption of patient-centric reimbursement models to improve access to expensive opioid-induced constipation therapies
5.8. Influence of clinical guidelines advocating early intervention for opioid-induced constipation among palliative care populations
5.9. Role of telemedicine consultations in optimizing management strategies for opioid-induced constipation in rural healthcare settings
5.10. Emergence of over-the-counter opioid-induced constipation remedies and their effect on prescription market dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Opioid Induced Constipation Market, by Product Type
8.1. Introduction
8.2. Combination Therapies
8.3. Laxatives
8.3.1. Osmotic Laxatives
8.3.2. Stimulant Laxatives
8.3.3. Stool Softeners
8.4. Peripherally Acting Mu-Opioid Receptor Antagonists
8.4.1. Alvimopan
8.4.2. Methylnaltrexone
8.4.3. Naldemedine
8.4.4. Naloxegol
9. Opioid Induced Constipation Market, by Oral
9.1. Introduction
9.2. Liquid
9.2.1. Solutions
9.2.2. Suspensions
9.3. Solid
9.3.1. Capsules
9.3.2. Tablets
10. Opioid Induced Constipation Market, by Rectal
10.1. Introduction
10.2. Enemas
10.3. Suppositories
11. Americas Opioid Induced Constipation Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Opioid Induced Constipation Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Opioid Induced Constipation Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. AstraZeneca plc
14.3.2. Shionogi & Co., Ltd.
14.3.3. H. Lundbeck A/S
14.3.4. Bausch Health Companies Inc.
14.3.5. Mundipharma International Limited
14.3.6. Merck & Co., Inc.
14.3.7. Valinor Pharma, LLC
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. OPIOID INDUCED CONSTIPATION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. OPIOID INDUCED CONSTIPATION MARKET: RESEARCHAI
FIGURE 22. OPIOID INDUCED CONSTIPATION MARKET: RESEARCHSTATISTICS
FIGURE 23. OPIOID INDUCED CONSTIPATION MARKET: RESEARCHCONTACTS
FIGURE 24. OPIOID INDUCED CONSTIPATION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. OPIOID INDUCED CONSTIPATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STIMULANT LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ALVIMOPAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALDEMEDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ENEMAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 91. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 94. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 95. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 96. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 97. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 98. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 99. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 100. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 101. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 102. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 103. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 104. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 105. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 106. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 107. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 108. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 109. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 110. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 111. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 112. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 113. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 114. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 115. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 116. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 117. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 118. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 177. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 178. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 179. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 180. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 181. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 182. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 183. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 184. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 185. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 186. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 187. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 188. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 189. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 190. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 191. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 192. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 193. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 194. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 195. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 196. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 197. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 198. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 199. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 200. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 201. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 202. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 203. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 204. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 219. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 220. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 221. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 222. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 223. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 224. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 225. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 226. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 227. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 228. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 229. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 230. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 231. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 232. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 233. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 234. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 235. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 236. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 237. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 238. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 239. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 240. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 241. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 242. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 243. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 244. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 245. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 246. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 289. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 290. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 291. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 292. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 293. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 294. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 295. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 296. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 297. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 298. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 299. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
TABLE 300. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY SOLID, 2025-2030 (USD MILLION)
TABLE 301. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2018-2024 (USD MILLION)
TABLE 302. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY RECTAL, 2025-2030 (USD MILLION)
TABLE 303. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 304. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 305. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
TABLE 306. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LAXATIVES, 2025-2030 (USD MILLION)
TABLE 307. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 308. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 310. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 311. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 312. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Opioid Induced Constipation market report include:
  • AstraZeneca plc
  • Shionogi & Co., Ltd.
  • H. Lundbeck A/S
  • Bausch Health Companies Inc.
  • Mundipharma International Limited
  • Merck & Co., Inc.
  • Valinor Pharma, LLC

Table Information